Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive taiwan study reveals COVID-19 treatment patterns

NCT ID NCT06085924

Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study used health records from over 8 million people in Taiwan to understand the effects of COVID-19 and how well the oral treatment nirmatrelvir/ritonavir works. Researchers looked at who got severely ill, needed hospital care, or died, and compared those who took the treatment with those who did not. The goal was to learn more about the disease and the real-world use of this medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,315,187 people

The number who actually took part.

Started

Nov 2023

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study data will be retrospectively collected from the National Health Insurance Research Database (NHIRD). The NHIRD is a nation-wide claims database in Taiwan, which contains anonymized patient-level claims data covering 99.9% of the entire 23 million Taiwanese population.

Ages

0 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohort 1: Inclusion Criteria: * Patients of all ages * Patients with a diagnosis of COVID-19 infection between 01 January 2021 and 31 December 2021 * Cases of patients registered in the databases Exclusion Criteria: * Patients without COVID-19 diagnosis Cohort 2: Inclusion Criteria: * ≥12 years of age * Have COVID-19 diagnosis with international classification of diseases (ICD) code between 01 January 2022 and 31 December 2022 Exclusion Criteria: * Patients without COVID-19 diagnosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID -19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID -19

Contacts and locations

Locations

  • Pfizer Taiwan

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.